BCL2 and acute myeloid leukemia: Since BETi treatment attenuated expressions of several BCL2 family of antiapoptotic proteins11–13,21, to further lower the threshold for apoptosis and enhance clinical anti-AML efficacy of BETi, a logical approach would be to concomitantly target and inhibit activity of the antiapoptotic proteins.